^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.

Published date:
05/20/2015
Excerpt:
This is a phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) amplified tumors treated with AZD4547 80mg twice daily...Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC...
DOI:
10.1200/jco.2015.33.15_suppl.2508
Trial ID: